New combo aims to reboot radioactive iodine in stubborn thyroid cancers
NCT ID NCT02152995
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This phase 2 trial tests whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has returned or spread and no longer responds to RAI alone. About 34 adults with specific genetic types of thyroid cancer will receive trametinib followed by a radioactive iodine scan and treatment. The goal is to see if the combination can slow cancer growth or shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.